Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US OKs PhotoCure's actinic keratosis therapy:

This article was originally published in Clinica

Executive Summary

PhotoCure has gained US approval for its photodynamic therapy for actinic keratosis, a sun-induced, pre-cancerous skin condition. The treatment involves the local application of a methyl aminolevulinate cream - currently called Metvix - and illumination with a proprietary red light source (CureLight/Aktilite) to activate the drug. The US approval is contingent on the FDA's acceptance of a tradename other than Metvix, which is similar to that of another dermatology product. The new tradename is expected in several weeks, said the Oslo, Norway firm. As a result of the approval, PhotoCure is entitled to receive a milestone payment of Euros3m ($3.66m) from Galderma, its sales and marketing partner outside the Nordic region. Metvix is already approved in 18 European countries, New Zealand and Australia.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059391

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel